Betamethasone
| Evidence Level: L4 | Predicted Indications: 7 |
Table of Contents
Betamethasone: Alopecia mucinosa
One-Sentence Summary
Betamethasone is a corticosteroid with 20 valid single-ingredient licences in Canada, mostly topical brands. The TxGNN model predicts it may be useful for alopecia mucinosa (alopecia mucinosa). Evidence is thin: no clinical trials and 1 publication, a 1964 case series with a therapy review.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Alopecia mucinosa |
| TxGNN Prediction Score | 0.9997 |
| Evidence Level | L4 |
| Canada Market Status | Marketed (marketed DINs on record: at least 20) |
| Number of DINs | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in the data compiled for this report. Betamethasone is a corticosteroid, a class with broad anti-inflammatory and immunosuppressive activity.
Follicular mucinosis (alopecia mucinosa) involves mucin deposition in hair follicles with perifollicular inflammation. An anti-inflammatory corticosteroid is therefore a plausible fit. This is a reasoned hypothesis, not a demonstrated effect. The only supporting source is a 1964 case series with a therapy review, and no modern studies are available.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 14164963 | 1964 | Case series/Review | Archives of dermatology | Report of three cases of follicular mucinosis (alopecia mucinosa) with a review of therapy; no abstract is available. |
Canada Market Information
At least 20 valid single-ingredient licences are recorded, and the list may be partial. The licence records carry no dosage form or approved-indication text. Main authorisations:
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 00323071 | DIPROSONE | Not available | Not available |
| 00653209 | TEVA-ECTOSONE | Not available | Not available |
| 00716618 | BETADERM CRM 0.05% | Not available | Not available |
| 00809187 | TEVA-TOPISONE | Not available | Not available |
| 00629367 | DIPROLENE | Not available | Not available |
Safety Considerations
- Drug Interactions: 100 interactions are recorded. Examples include a Major interaction with adalimumab. Moderate interactions include zidovudine, isotretinoin, acarbose, acebutolol, acetazolamide, ketorolac, nifedipine, ibuprofen, ethinylestradiol, aldesleukin, alemtuzumab, fluvoxamine and fosamprenavir. Minor interactions include formoterol and salbutamol.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is high, but the only evidence is a single 1964 case series with no trials. The mechanistic link is plausible but untested. Because that study directly addresses this disease, the evidence level is L4, the lowest tier above model prediction alone.
To proceed, the following is needed:
- Package insert warnings and contraindications
- Mechanism of action data
- Modern case series or controlled studies of corticosteroids in follicular mucinosis
- Route and formulation compatibility assessment (topical versus intralesional)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.